The molecular pathogenesis of the NUP98-HOXA9 fusion protein in acute myeloid leukemia by Rio-Machin, A et al.
1 
 
The molecular pathogenesis of the NUP98-HOXA9 fusion protein in Acute 1 
Myeloid Leukemia 2 
Ana Rio-Machin 1,2; Gonzalo Gomez-Lopez 3; Javier Muñoz 4; Fernando Garcia-Martinez 4; Alba 3 
Maiques-Diaz 1; Sara Alvarez 1; Rocio N Salgado 1; Mahesh Shrestha 5; Raúl Torres 6; Claudia Haferlach 4 
7; Maria Jose Larrayoz 8; Maria Jose Calasanz 8; Jude Fitzgibbon 2 and Juan C. Cigudosa 1 5 
1 Molecular Cytogenetics Group, Human Cancer Genetics Programme, Centro Nacional Investigaciones 6 
Oncologicas (CNIO), Madrid, Spain  7 
2 Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, UK 8 
3 Bioinformatics Unit, Centro Nacional Investigaciones Oncologicas (CNIO), Madrid, Spain 9 
4 Proteomics Unit, Centro Nacional Investigaciones Oncologicas (CNIO), Madrid, Spain. ProteoRed-ISCIII. 10 
5 Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, 11 
Cincinnati, OH, USA 12 
6 Viral Vector Facility, Fundacion Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain 13 
7 MLL Münchner Leukämielabor, München, Germany 14 
8 Department of Genetics and Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, 15 
Spain  16 
 17 
Corresponding author: 18 
Ana Rio-Machin, PhD 19 
Centre for Haemato-Oncology 20 
Barts Cancer Institute  21 
Queen Mary University of London 22 
John Vane Science Centre, Charterhouse Square, 23 
London EC1M 6BQ (United Kingdom) 24 
Tel: +44 (0)20 7882 8780   25 
Email: a.rio-machin@qmul.ac.uk 26 
 27 
DISCLOSURE OF CONFLICTS OF INTEREST 28 




Recurrent chromosomal translocations are common initiation events and have provided 31 
important insights into the pathogenesis of AML, paving the way for the introduction of novel targeted 32 
therapies. However, clinical outcomes, in particular for patients with adverse cytogenetic features 33 
remain suboptimal. The chromosomal translocation t(7;11)(p15, p15), encoding the fusion protein 34 
NUP98-HOXA9 (NHA9), is a rare poor risk cytogenetic event in AML associated with  a particularly poor 35 
prognosis. NHA9 brings the FG repeat-rich portion of the nucleoporin NUP98 upstream of the 36 
homeodomain and PBX heterodimerization domains of HOXA9, and acts as oncogenic transcription 37 
factor 1. The pathogenic events underlying NHA9 remain poorly understood and herein, we aim to 38 
characterize the downstream mediators of this oncoprotein by determining the effects of the fusion 39 
using human cellular models. 40 
We set out initially to compare the DNA binding sites of NHA9, HOXA9 and NUP98, by forced 41 
expression of these genes alone or the corresponding fusion gene by retroviral transduction of 42 
HEK93FT cell line and cord blood-isolated human hematopoietic progenitors (hHP). ChIP-seq analysis 43 
in the HEK293FT cellular model identified 4 471 significant genomic regions (false discovery rate (FDR) 44 
< 0.05) as target sites of the fusion protein, all located within -5/+ kb from the annotated Transcription 45 
Start Site (TSS) (Figure S1A). They correspond to 1 368 genes and 17 miRNAs (Table S1) of which 399 46 
genes were also shown to be common targets of HOXA9 and 4 of NUP98 (Figure 1A, Table S2, Figures 47 
S1C-D) [See supplementary methods] (Data deposited in GEO http://www.ncbi.nlm.nih.gov/geo/, 48 
accession number: GSE62587). Ingenuity pathway analysis of the NHA9 target series demonstrated a 49 
significant enrichment of pathways associated with tumorigenesis and leukemic differentiation 50 
(Figure S1B).  51 
We next performed a detailed sequence analysis of the NHA9 binding sites using the MEME-ChIP 52 
algorithm and detected a significant overlap with binding of several HOX genes, including HOXA9, 53 
supporting a role for this homeodomain in the DNA binding of NHA9. Strikingly, NHA9 sites were 54 
enriched for a novel binding motif, CA/gTTT, that was present in one-third (n = 1 421) of all NHA9 ChIP-55 
seq regions (Table S3). This motif had not been previously associated with any known transcription 56 
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factor and was not observed in wild type HOXA9 or NUP98 binding site experiments, suggesting that 57 
it is specific to NHA9 DNA binding. MEME-ChIP (SpaMO) was used to identify significant co-58 
occurrences of other known DNA binding motifs with this novel NHA9 DNA binding motif. Binding 59 
motifs corresponding to 12 transcription factors, including other HOX family proteins such as HOXB7 60 
or HOXD11, were found to be overrepresented within the region adjacent to CA/gTTT (Table S4), 61 
suggesting a possible functional cooperation with the fusion oncoprotein.  62 
As the NHA9 target motifs are preferentially located more than 1 kb upstream/downstream of 63 
the TSS (Figure S1A), we reasoned that NHA9 binding may coincide with particular enhancer elements. 64 
A similar distribution was also found for the identified HOXA9 target regions whereas NUP98 binding 65 
sites were mostly located within promoters, both in agreement with previous studies 2, 3. We selected 66 
eight leukemia-related genes (MEIS1, HOXA9, PBX3, MET, BRAF, AF9, PTEN and NF1) identified as part 67 
of our NHA9 ChIP-seq experiments, for locus specific qChIP studies. A significant enrichment of 68 
H3K4me1, a chromatin mark that predicts poised and active enhancers, and RNA Polymerase II (PolII), 69 
which is consistent with the presence of the active form of the enhancers 4, 5, was shown within the 70 
NHA9 binding sites upstream of the eight genes (Figures 1B and S1E). NHA9 expression levels were 71 
demonstrated to be comparable in our two cellular models (HEK293FT and hHP) (Figure S1G). 72 
Accordingly, we validated the ChIP-seq results in the HEK293FT model (Figure S1F)  using the same set 73 
of eight NHA9 target genes and also demonstrated binding of NHA9 to the eight enhancers in our 74 
second model system of NHA9-expressing hHP cells (Figure 1C), allowing us to confirm these findings 75 
in primary human hematopoiesis. 76 
We next focused attention on the  transcription factors MEIS1, HOXA9 and PBX3, as their 77 
overexpression is significantly related to adverse prognosis in AML (The Cancer Genome Atlas 6; Figure 78 
S1H) and were previously reported to drive leukemogenesis through the formation of a transcriptional 79 
activator complex 7. To test the importance of these three transcription factors in NHA9 pathogenesis, 80 
we completed reporter assays in HEK293FT cells by cloning the identified enhancers of MEIS1, HOXA9 81 
or PBX3 into a luciferase reporter vector. A significant 1.6-2.8 fold induction in luciferase activity was 82 
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observed when NHA9 was co-expressed for all three enhancers, indicating a direct induction of MEIS1, 83 
HOXA9 and PBX3 expression through the NHA9 interaction with their corresponding regulatory 84 
regions (Figure 1D) [see Supplementary Methods]. This observation was accompanied by upregulation 85 
of all 3 transcription factors and of three of their known target genes (MYB, MEF2C and FLT3) 7 in 86 
NHA9-expressing hHP cells (Figure 1E and S1I). Gene Expression Profiling performed in three 87 
independent NHA9-expressing hHP clones and AMLs from 5 patients with t(7;11)(p15,p15), confirmed 88 
MEIS1-HOXA9-PBX3 overexpression and it was further validated by RT-qPCR analysis in 3 additional 89 
NHA9 primary samples (Figure S2A). These observations suggested that the NHA9-expressing hHP cells 90 
can be sensitive to HXR9, a specific peptide inhibitor of HOXA9 and PBX3 interaction that leads to 91 
disruption of the MEIS1-HOXA9-PBX38 complex. We tested this hypothesis by treating these cells with 92 
HXR9 that resulted in a selective decrease in their viability (Figure 1F and S2B-D) [see Supplementary 93 
Methods] without affecting cell differentiation (data not shown), therefore confirming the relevance 94 
of these downstream mediators in driving the oncogenic activity of NHA9. 95 
In order to explore other mechanisms driving NHA9 pathogenesis and to better understand its 96 
role in transcriptional regulation, we interrogated our ChIP-seq and gene expression profiling data, 97 
which revealed both activation and repression of gene expression induced by this fusion oncoprotein 98 
(Figure 2A). The cooperation of MLL1 and CRM1 with NHA9 in the upregulation of some target genes 99 
has been shown recently by Xu et al. 9, 10, which was also supported by comparing NHA9 target genes 100 
identified in our ChIP-seq experiments with MLL1 and CRM1 targets. We found that 25% and 35% of 101 
NHA9 target genes were also in common with MLL1 and CRM1 target genes, respectively (Figure S2E). 102 
Notably, 151 target genes, including MEIS1 and HOXA9, were shared by all three proteins (NHA9, MLL1 103 
and CRM1), suggesting a possible cooperation among these transcription factors in NHA9-driven 104 
leukemias. It has also been reported that NUP98, through its FG repeat domain, may interact with 105 
transcriptional activator p300 and repressor HDACs 11, allowing us to postulate that transcriptional 106 
effects of NHA9 in enhancers could be mediated by these regulators. We first demonstrated NHA9 107 
binding to both p300 and HDAC1 by Co-immunoprecipitation experiments (Figure 2B) [see 108 
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Supplementary Methods] and went on to examine their binding potential in a panel of eight regulatory 109 
regions of NHA9 target genes (four upregulated and four downregulated target genes) in the presence 110 
of the fusion protein by qChIP.  These experiments demonstrated selective binding of p300 to the 111 
regulatory regions of the upregulated genes MEIS1, HOXA9, PBX3 and AFF3 (Figure 2C), and of HDAC1 112 
to the downregulated genes BIRC3, SMAD1, FILIP1L and PTEN (Figure 2D). Altogether this data 113 
suggests that p300 and HDAC1 are selectively recruited by NHA9 at enhancer regions to modulate the 114 
expression of genes involved in leukemogenesis. 115 
As the interaction of NHA9 with HDAC1/2 was validated by mass spectrometry analysis using the 116 
NHA9-expressing HEK293FT model (Proteomics data have been deposited on the ProteomeXchange 117 
Consortium via the PRIDE partner repository, data set identifier PXD001828)) [see Supplementary 118 
Methods], we had a molecular rationale for testing HDAC inhibitors (HDACi) in NHA9 AML.  We 119 
assessed the sensitivity of the hHP-NHA9 model to the pan-HDACi LBH589 (Panobinostat) and 120 
observed a strong inhibitory effect that was significantly higher (IC50hHP-NHA9≈4nM) than its inhibitory 121 
effect in MLL-AF9 -expressing (IC50hHP-MLL_AF9≈30nM) or AML1-ETO-expressing (IC50hHP-122 
AML1_ETO≈200nM) hHP cells 12, 13, where the efficacy of this component has been already established 14, 123 
15 (Figure 2E). Accordingly, treatment with low doses (4nM) of LBH589 completely abrogated the 124 
ability of hHP-NHA9 cells to form colonies in the CFC assay (Figure S2F) and significantly induced 125 
apoptosis within 24h (4nM and 30nM doses), whereas LBH589 had no effect at the same doses on the 126 
empty vector control hHP cells (Figure S2G). It has to be noted that LBH589 did not induce 127 
differentiation in NHA9-expressing cells as no significant changes in the number of CD11b positive 128 
cells were observed by flow cytometry analysis post treatment (data not shown). These observations 129 
are in accordance with a recent report suggesting the combination of COX or DNMT inhibitors with 130 
HDACi for treatment of NHA9 AML patients 16, however in this study we identified the molecular 131 
rationale for HDACi therapy as well as a panel of target genes downstream of NHA9 that can be used 132 
as biomarkers for response to this treatment. Furthermore, our hHP-NH9A cellular model showed 133 
sensitivity to markedly lower concentrations of LBH589 (4nM) than the recommended doses in 134 
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preclinical studies and Multiple Myeloma Clinical Trials 17, 18, indicating that LBH589 could be safely 135 
used as novel targeted therapy for the treatment of NH9A AML patients. However, the biological 136 
consequences of this therapy, as well as the best dosage-time relation for the translation into clinics 137 
need to be further investigated.  138 
In summary, NHA9 deregulates the expression of key leukemic genes, including MEIS1-HOXA9-139 
PBX3 complex, through the enhancer binding and the direct interaction of the fusion protein with 140 
HDAC and p300 transcriptional regulators. The oncogenic effects of NHA9 can be overcome by HDACi 141 
treatment, demonstrating a significant inhibitory effects against NHA9-driven leukemic cells and 142 
suggesting a novel approach to treatment of this high-risk group of patients. 143 
 144 
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FIGURE 1 221 
 222 
 223 
Figure 1: NUP98-HOXA9 binds to enhancers of genes related to leukemogenesis (A) Venn diagrams 224 
of NHA9, HOXA9 and NUP98 target genes identified by ChIP-seq experiments on HEK293FT human 225 
models and located within +5/-5 kb of an annotated Transcrption Start Site (TSS). Significant ChIP-seq 226 
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peaks were established at FDR ≤ 5%. (B) H3K4me1 qChIP fold enrichment in the selected NHA9 target 227 
regions using anti-H3K4me1 antibody. The MEIS1 promoter region was used as a negative control. The 228 
average of three experiments is shown. Error bars represent SEM. (C) NHA9 qChIP fold enrichment on 229 
the eight selected NHA9 target enhancer regions using anti-FLAG antibody in the NHA9 expressing 230 
hHP cellular model. The average of 3 experiments is shown. Error bars represent SEM. (D) Luciferase 231 
assay was performed to analyze the role of NHA9 in regulating the expression of HOXA9, PBX3 and 232 
MEIS1. The luciferase constructs containing the enhancer region (using pGL3-Promoter vector, 233 
Promega Biotech Ibérica S.L) of HOXA9, PBX3 and MEIS1 were co-transfected into HEK293FT cells with 234 
the expression vector pMSCV-NHA9, together with Renilla vector for the purpose of normalization. 235 
Luciferase activity was determined 48 h after reporter plasmid transfection in all cases. A significant 236 
increase in luciferase activity induced by NHA9 expression was observed in each case, confirming a 237 
direct increase of MEIS1, HOXA9 and PBX3 expression through NHA9 interaction with their 238 
corresponding enhancer regions. Data are presented as the mean value from two separate 239 
experiments with n=3 for each experiment. Error bars represent SEM. (E) Expression analysis by qRT-240 
PCR of MEIS1, HOXA9 and PBX3 in the NHA9 expressing hHP cellular model. The expression of the 241 
endogenous human housekeeping gene GAPDH was used to normalize the data, which are expressed 242 
as the mean of 2-ΔCt values obtained for each sample after normalization based on the hHP-empty 243 
vector model. (F) Analysis of the hHP-NHA9 response to HXR9 and CXR9 (control) peptides. hHP-NHA9 244 
cells were plated in 96-well plates in triplicate and exposed to 13uM of HXR9/CXR9. Cell viability was 245 
assessed at different time points. Average normalized optical density (OD) values of three 246 
independent experiments are shown. 247 
Statistical significance for relative enrichment and proliferation was determined at p < 0.05 (*), p < 248 
0.01 (**) and p < 0.001 (***), using a t-test with Bonferroni correction. N.S corresponds to non-249 





FIGURE 2 253 
 254 
Figure 2: NUP98-HOXA9 has an activator-repressor role in transcriptional regulation driven by p300 255 
and HDAC1 interactions.  (A) We applied gene set enrichment analysis (GSEA) to test for enrichment 256 
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of NHA9 ChIP-seq target gene set among differentially expressed genes using expression array data 257 
from hHP-NHA9 cellular model (left panel) and five NHA9 primary samples (right panel). Genes were 258 
ranked based on the limma-moderated t statistic. After Kolmogorov-Smirnoff testing, those gene sets 259 
with FDR <0.25, a well-established cut-off for the identification of biologically relevant gene sets, were 260 
considered enriched (B) Analysis of NHA9 and p300/HDAC1 interactions by co-immunoprecipitation. 261 
HEK293FT cells were transfected with pMSCV-NUP98-HOXA9 or pMSCV-empty vectors. 48h post-262 
transfection, the immunoprecitpitation was performed using anti-p300 and anti-HDAC1 antibodies 263 
and the proteins were analyze by immunoblotting using anti-FLAG antibody. Endogenous GAPDH 264 
protein levels were used as a loading control. (C & D) qChIP fold enrichment of p300 and HDAC1 in 265 
the regulatory regions of four upregulated (C) and four downregulated (D) target genes of NHA9. The 266 
average of 3 experiments showed the binding, along with the fusion protein, of p300 and HDAC1 to 267 
the regulatory regions of the overexpressed and downregulated NHA9-target genes, respectively. (E) 268 
Analysis of the hHP-NHA9 response to HDAC inhibitors. Cells were exposed for 72 hours to serial 269 
dilutions of panobinostat (LBH589) followed by the addition of WST-1 to assess cell viability. The 270 
average normalized optical density (OD) values are shown compared to vehicle.  271 
Statistical significance for relative enrichment and proliferation was determined at p < 0.05 (*), p < 272 
0.01 (**) and p < 0.001 (***), using a t-test with Bonferroni correction. N.S corresponds to non-273 
significant comparisons. Error bars represent SEM.  274 
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